DIOSynVax is pioneering a novel approach to vaccine antigen design, focusing on the development of Vaccine Antigen Payloads (VAPs) that enhance the effectiveness of vaccines against a wide range of existing and emerging viruses. Their methodology is rooted in a deep understanding of virus structure and evolution, utilizing a combination of computational biology and rigorous validation through in vitro and in vivo studies. This innovative process allows DIOSynVax to create custom-designed antigens that provide broad and deep protection, addressing the limitations of traditional vaccine strategies that often fail to anticipate viral mutations.

The company's technology is vector-agnostic, meaning that their VAPs can be integrated into various vaccine delivery systems, including nucleic acid-based platforms like DNA and mRNA vaccines, as well as viral vector and protein-based vaccines. DIOSynVax employs advanced computational modeling to identify and incorporate key immune targets into their antigen designs, while also leveraging a self-improving algorithm that continuously refines their approach based on accumulated data. This dynamic system not only enhances the immediate efficacy of vaccines but also positions DIOSynVax to proactively address future pandemic threats by anticipating viral changes and developing robust vaccine candidates.

United Kingdom

DIOSVax is a biotech startup working to revolutionise the way humanity protects itself from infectious disease and emerging pathogens.

The company is named after its core technology, DIOSynVax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines), a new system that will significantly accelerate vaccine development and achieve dramatic improvements to the protection against emerging and re-emerging pathogens.

DIOSynVax

Company Details